LIXTE Biotechnology Holdings (NASDAQ: LIXT) reported its first-quarter 2026 financial results, emphasizing progress in its oncology pipeline and corporate expansion. The company filed its Form 10-Q for the quarter ended March 31, 2026, detailing the advancement of its lead candidate LB-100, a first-in-class PP2A inhibitor. Notably, the company has expanded its ovarian cancer trial following favorable safety data from a combination study with immunotherapy.
LB-100 is being evaluated in proof-of-concept clinical trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. The compound has demonstrated tolerability at doses associated with anti-cancer activity, and preclinical data suggest it may enhance the efficacy of chemotherapies and immunotherapies. LIXTE’s approach is based on a novel concept called activation lethality, which targets a new field of cancer biology. The company holds a comprehensive patent portfolio protecting its technology.
Beyond its clinical pipeline, LIXTE is pursuing strategic expansion through its wholly owned subsidiary, Liora Technologies Europe Ltd. Liora is developing the LiGHT System, an electronically controlled proton therapy platform for treating tumors. The company believes this technology offers advantages over existing proton therapy systems. The subsidiary has shown continued growth during the quarter, contributing to LIXTE’s broader strategy to strengthen its oncology treatment development capabilities.
LIXTE is a clinical-stage pharmaceutical and med-tech company focused on cancer drug development. Additional information about the company and its programs can be found at www.lixte.com. For more on Liora Technologies, visit www.lioratechnologies.com. The full press release is available at https://ibn.fm/oHzhK.
